Australian Vintage [ASX:AVG] Shares Jump 10% as It Undertakes Strategic Review
Australian Vintage shares jump 10% as the company announces a strategic review to unlock shareholder value. The review will be run by the corporate advisory firm E&P.
Australian Vintage shares jump 10% as the company announces a strategic review to unlock shareholder value. The review will be run by the corporate advisory firm E&P.
By Charlie Ormond,
United Malt shares jump 8.98% this afternoon after announcing Malteries Soufflet signed a deal to buy out the craft beer and distillery producer for $5 per share. The deal still needs sign-off but could be a big move for malt producers worldwide.
By Charlie Ormond,
Integrated services giant Downer Edi announced today that it had secured a $4.6 billion contract with the QLD Government to build and maintain 65 new trains for Brisbane. The announcement saw Downers shares rise by 2.41%, trading at $4.035 per share.
By Charlie Ormond,
Medibank faces a $250 million capital reserve requirement as punishment by the APRA for last October’s massive data breach in which the data of 9.7 million customers was stolen. Shares have remained resilient to the news, up by 1.71%, trading at $3.56 per share.
By Charlie Ormond,
Best & Less Group Holdings made news by announcing softening trading conditions as total sales went down by 11.7%. In response, BST began clearing winter stock to meet current demand and maintain inventory quality.
By Charlie Ormond,
Today, Rio Tinto announced that it will invest more than US$800 million (AU$1.18 billion) into its Kennecott operation. With the investment, RIO plans to increase copper production, expand its underground mine and upgrade processing at its new smelter.
By Charlie Ormond,
Today, the ACCC Tribunal blocked an appeal by Telstra and TPG for the proposed MOCN deal between the two. The regional network deal was worth approximately $1.8 billion and would have seen the two telcos share network assets in direct competition with Optus.
By Charlie Ormond,
Avita Medical shares are down by 4.2% despite positive news as the company announces FDA approval of its breakthrough RECELL skin repair system for vitiligo patients.
By Charlie Ormond,
Biome Australia shares are up by 16.18% after news FY23 sales revenue target of $7 million has been hit with half a month of trading remaining in the quarter. This is after their flagship Activated Probiotics product range finds interest through distribution channels growth throughout Australia, the UK, and NZ.
By Charlie Ormond,
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988